Management of Hyperglycemia with the Administration of Intravenous Exenatide to Patients in the Cardiac Intensive Care Unit.

Link to article at PubMed

Management of Hyperglycemia with the Administration of Intravenous Exenatide to Patients in the Cardiac Intensive Care Unit.

Endocr Pract. 2012 Nov 27;:1-29

Authors: Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, Marso SP

Abstract

Objective: To evaluate the feasibility, effectiveness, and safety of intravenous exenatide to control hyperglycemia in the cardiac intensive care unit (CICU).Methods: A prospective, single-center, open-label, non-randomized, pilot study. Forty patients admitted to the CICU with glucose levels of 140-400mg/dl received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours. Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90-119 mg/dl (n=84), and the other (MOD) with a target of 100-140 mg/dl (n=71).Results: Median admission glucose values were 185.5 mg/dl (161.0, 215.5), 259.0 mg/dl (206.0, 343.0), and 189.5 mg/dl (163.5, 245.0) in the exenatide, MOD and INT groups, respectively (p< 0.001). Steady state glucose values were similar between the exenatide [132.0 mg/dl (110.0, 157.0)] and the MOD groups [127.0 mg/dl (105.0, 161.0), p=0.15], but lower in the INT group [105.0 mg/dl (92.0, 128.0), p <0.001 for exenatide vs. INT]. Median (IQR) time to steady state was 2.0 hours (1.5, 5.0) in the exenatide group compared to 12.0 hours (7.0, 15.0) in MOD group (P <0.001), and 3.0 hours (1.0, 5.0) in the INT group (P=0.80 for exenatide vs. INT). Exenatide was discontinued in 3 patients after failure to achieve glycemic control. No episodes of severe hypoglycemia (<50 mg/dl) occurred in patients who received exenatide. Nausea was reported by 16 and vomiting by 2 patients.Conclusion: Intravenous exenatide is effective in lowering glucose levels in CICU patients, but its use may be limited by nausea.

PMID: 23186969 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *